**Acknowledgements**

In addition to the author the Linköping Diabetes Immune Intervention study group consists of Ass.professor Rosaura Casas, PhD, Stina Axelsson PhD, Mikael Cheramy PhD,and PhD students Mikael Pihl and Linda Åkerman.

We are grateful to excellent technical assitance from Ingela Johansson and Gosia Smolinska, and from research nurses Eva Isacson and AnnMarie Sandström. All pediatricians involved in our studies are also gratefully acknowledged.

[7] Danne T, Kordonouri O, Holder M, Haberland H, Golembowski S, Remus K, Blasig S, Wadien T, Zierow S, Hartmann R, Thomas A. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy. Diabetes Technol

Immune Intervention in Type I Diabetes Mellitus

http://dx.doi.org/10.5772/52801

507

[8] Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev En‐

[9] Hovorka R, Allen JM, Elleri D, Chassin LJ, Harris J, Xing D, Kollman C, Hovorka T, Larsen AM, Nodale M, De PA, Wilinska ME, Acerini CL, Dunger DB. Manual closedloop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 rand‐

[10] Madsbad S, Alberti KG, Binder C, Burrin JM, Faber OK, Krarup T, and Regeur L: Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent

[11] Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial.

[12] Wahren J, Ekberg K, Jörnvall H. C-peptide is a bioactive peptide. Diabetologia. 2007

[14] Gonez LJ, Knight KR. Cell therapy for diabetes: stem cells, progenitors or beta-cell rep‐

[15] Ludvigsson J. C-peptide an adequate endpoint in type 1 diabetes. Diabetes Metab Res

[16] Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus

[17] Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, Raghu PK, Paquette TL. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science. 1983 Dec

[18] Baekkeskov S. Immunoreactivity to a 64,000 Mr human islet cell antigen in sera from insulin-dependent diabetes mellitus patients and individuals with abnormal glucose

[19] Savola K, Bonifacio E, Sabbah E, et al. IA-2 antibodies - a sensitive marker of IDDM with clinical onset in childhood and adolescence. Diabetologia 1998:41:424-9.

[20] Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A. 2007;104:17040-5.

with autoimmune polyendocrine deficiencies. Lancet 1974:2:1279-82.

[13] Jun HS. Regeneration of pancreatic beta cells. Front Biosci. 2008 May 1;13:6170-82

Ther. 2011;13:1–6

docrinol. 2011;7:385–395.

omised crossover trial. Lancet. 2010;375:743–751

lication?Mol Cell Endocrinol. 2010 Jul 8;323(1):55-61.

tolerance. Mol Biol Med. 1986 Apr;3(2):137-42

diabetes. Br Med J 2: 1257-1259, 1979.

Diabetes Care 2003;26:832-6.

Rev. 2009 Nov;25(8):691-3.

23;222(4630):1337-9.

Mar;50(3):503-9.

Our studies on immune intervention have been generously supported by Barndiabetesfonden (Swedish Child Diabetes Foundation), Swedish Research Council, Research Council of South‐ east Sweden ( FORSS), and the mechanistic studies are supported by Juvenile Diabetes Re‐ search Foundation (JDFR).
